<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712435</url>
  </required_header>
  <id_info>
    <org_study_id>33788420.4.0000.0072</org_study_id>
    <nct_id>NCT04712435</nct_id>
  </id_info>
  <brief_title>Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>ALISON</acronym>
  <official_title>Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Brasileiro de Controle do Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Brasileiro de Controle do Cancer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sinusoidal obstruction syndrome (SOS) or hepatic veno-occlusive disease (VOD) is a serious&#xD;
      complication that occurs, most often occurring in patients undergoing hematopoietic stem cell&#xD;
      transplantation (HSCT), especially in its first thirty days. The morbidity and mortality in&#xD;
      this syndrome are considerable, since severe SOS is associated with a mortality of more than&#xD;
      90% in the first hundred days of HSCT.&#xD;
&#xD;
      Some risk factors are modifiable, especially those related to transplantation, but when&#xD;
      non-alterable factors are present, preventive measures are needed that can reduce the&#xD;
      incidence and / or severity of SOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, placebo-controlled study to evaluate the efficacy and&#xD;
      safety of N-acetylcysteine as prophylaxis of sinusoidal obstruction syndrome in patients&#xD;
      undergoing hematopoietic stem cell transplantation Up to date, no approved medications are&#xD;
      available for prophylactic treatment of sinusoidal obstruction syndrome in patients&#xD;
      undergoing hematopoietic stem cell transplantation. N-acetylcysteine is a drug that has been&#xD;
      long used as a mucolytic. And placebo responses contribute to help assess the appropriateness&#xD;
      of randomized clinical trials in determining the size of drug effect.&#xD;
&#xD;
      The study will enroll patients undergoing hematopoietic stem cell transplantation to receive&#xD;
      sequentially one of two treatment: N-acetylcysteine or Placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center, randomized, placebo-controlled study to evaluate the efficacy and safety of N-acetylcysteine</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Matching placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of SOS</measure>
    <time_frame>Day + 30 post HSCT</time_frame>
    <description>To evaluate if prophylactic of N-acetylcysteine has an impact on the incidence of Sinusoidal obstruction syndrome (SOS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of SOS</measure>
    <time_frame>within 30 days of bone marrow transplant</time_frame>
    <description>Death as noted in medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinusoidal obstruction syndrome (SOS) -Free Survival at Day 30 Post-Hematopoietic Stem Cell Transplant (HSCT)</measure>
    <time_frame>30 Days Post-Transplant</time_frame>
    <description>Comparison of efficacy of N-acetylcysteine vs Placebo for the prevention of SOS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sinusoidal Obstruction Syndrome (SOS)</condition>
  <condition>Hematopoietic Stem Cell Transplant (HSCT)</condition>
  <arm_group>
    <arm_group_label>Experimental: N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sachets containing N-acetylcysteine 200 mg Powder for Oral Solution administered every 8 hours (Daily dose 600 mg/day). is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200mg granulated solution of matching placebo administered every 8 hours (Daily dose 600 mg/day), is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo</description>
    <arm_group_label>Experimental: N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  A proven diagnosis of one of the hematological malignancies: Acute Myeloid Leukemia,&#xD;
             Acute Lymphoid Leukemia, Chronic Myeloid Leukemia, Chronic Lymphoid Leukemia, Multiple&#xD;
             Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma&#xD;
&#xD;
          -  Patients must be scheduled to undergo of Allogeneic hematopoietic transplantation or&#xD;
             HLA (Human Leukocyte Antigen) haploidentical related or Unrelated or HLA-matched&#xD;
             related or autologous stem cell transplant&#xD;
&#xD;
          -  Patients must be able to understand and sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a serious active disease or co-morbid medical condition, as judged by the&#xD;
             investigator, which would interfere with the conduct of this study&#xD;
&#xD;
          -  Patient, in the opinion of the investigator, may not be able to comply with the safety&#xD;
             monitoring requirements of the study&#xD;
&#xD;
          -  Known hypersensitivity to N-acetylcysteine&#xD;
&#xD;
          -  Contraindications to perform any procedure provided for in this study&#xD;
&#xD;
          -  Patients who have already undergone a previous transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamilla N Cavalcante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBCC Oncologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamilla N Cavalcante, MD</last_name>
    <phone>+55113474-4428</phone>
    <email>millacavalcante@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alayne D Yamada, PhD</last_name>
    <phone>+55113474-4242</phone>
    <email>alayne.pesquisa@ibcc-mooca.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jamilla Neves Cavalcante</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Jamilla N Cavalcante, MD</last_name>
      <phone>+55113474-4428</phone>
      <email>millacavalcante@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alayne D Yamada, PhD</last_name>
      <phone>+55113474-4242</phone>
      <email>alayne.pesquisa@ibcc-mooca.org.br</email>
    </contact_backup>
    <investigator>
      <last_name>Jamilla N Cavalcante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Cristina M Macedo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larissa Y Okada, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauro Augusto C Leite, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.</citation>
    <PMID>24102514</PMID>
  </reference>
  <reference>
    <citation>Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Duarte RF, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Pagluica T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52. Epub 2015 Mar 23. Review.</citation>
    <PMID>25798682</PMID>
  </reference>
  <reference>
    <citation>Dalle JH, Giralt SA. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biol Blood Marrow Transplant. 2016 Mar;22(3):400-9. doi: 10.1016/j.bbmt.2015.09.024. Epub 2015 Oct 23. Review.</citation>
    <PMID>26431626</PMID>
  </reference>
  <reference>
    <citation>Ã–zdemir ZC, Turhan AB, Eren M, Bor Ã–. Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity? Blood Res. 2017 Mar;52(1):69-71. doi: 10.5045/br.2017.52.1.69. Epub 2017 Mar 27.</citation>
    <PMID>28401107</PMID>
  </reference>
  <reference>
    <citation>Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, Karlsson H, Brune M, Hassan M, Mattsson J, RingdÃ©n O. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008 May;41(9):785-90. doi: 10.1038/sj.bmt.1705969. Epub 2008 Jan 7.</citation>
    <PMID>18176610</PMID>
  </reference>
  <reference>
    <citation>RingdÃ©n O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000 May;25(9):993-6.</citation>
    <PMID>10800069</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Brasileiro de Controle do Cancer</investigator_affiliation>
    <investigator_full_name>Jamilla Neves Cavalcante</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stem cell transplant</keyword>
  <keyword>Hematopoietic stem cell transplant (HSCT)</keyword>
  <keyword>Sinusoidal obstruction syndrome (SOS)</keyword>
  <keyword>Veno-occlusive disease (VOD)</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

